Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$29.49−$0.6500 (−2.16%) on the dayAs of the close; data may be delayed.
AMLX price, last 12 months
Key stats
- Previous close
- $30.14
- Open
- $30.28
- Day range
- $29.47 – $30.70
- 52-week range
- $10.83 – $41.14
- Volume
- 1.3M
- Avg volume (20 days)
- 1.6M
- Market cap
- $3.8B
Performance
1W−9.0%
1M−20.5%
3M+65.8%
6M+118.9%
YTD+144.1%
1Y+112.5%
vs S&P 500, 1Y+95.7 pts
Technicals and fundamentals
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $3.8B